argenx SE – NASDAQ:ARGX
argenx SE stock price today
$656.89
+30.58
+4.88%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 9 hours
argenx SE stock price monthly change
+34.28%
month
argenx SE stock price quarterly change
+34.28%
quarter
argenx SE stock price yearly change
+62.04%
year
argenx SE key metrics
Market Cap | 37.40B |
Enterprise value | 19.96B |
P/E | -27.64 |
EV/Sales | 48.59 |
EV/EBITDA | -27.51 |
Price/Sales | 50.51 |
Price/Book | 7.37 |
PEG ratio | 0.43 |
EPS | -5.68 |
Revenue | 1.40B |
EBITDA | -231.29M |
Income | -327.92M |
Revenue Q/Q | 82.98% |
Revenue Y/Y | 132.28% |
Profit margin | -172.76% |
Oper. margin | -175.37% |
Gross margin | 92.83% |
EBIT margin | -175.37% |
EBITDA margin | -16.42% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeargenx SE stock price history
argenx SE stock forecast
argenx SE financial statements
Average Price Target
$660
Potential upside: 0.47%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 270.55M | -94.36M | -34.88% |
|---|---|---|---|
| Sep 2023 | 329.78M | -72.64M | -22.03% |
| Dec 2023 | 407.43M | -99.31M | -24.38% |
| Mar 2024 | 401.00M | -61.59M | -15.36% |
| 2022-10-27 | -5.32202 | -4.26 |
|---|---|---|
| 2022-12-31 | 1.24 | -0.69744 |
| 2023-03-02 | -0.7 | -0.7 |
| Jun 2023 | 3193791000 | 335.74M | 10.51% |
|---|---|---|---|
| Sep 2023 | 0 | 0 | |
| Dec 2023 | 4542458000 | 444.95M | 9.8% |
| Mar 2024 | 0 | 0 |
| Jun 2023 | -258.49M | 500.47M | 62.38M |
|---|---|---|---|
| Sep 2023 | 0 | 0 | 0 |
| Dec 2023 | -69.55M | -284.69M | 1.27B |
| Mar 2024 | 0 | 0 | 0 |
argenx SE alternative data
| Sep 2023 | 843 |
|---|---|
| Oct 2023 | 843 |
| Nov 2023 | 843 |
| Dec 2023 | 843 |
| Jan 2024 | 843 |
| Feb 2024 | 843 |
| Mar 2024 | 1,148 |
| Apr 2024 | 1,148 |
| May 2024 | 1,148 |
| Jun 2024 | 1,148 |
| Jul 2024 | 1,148 |
argenx SE other data
63.05%
+5.90%
of ARGX is owned by hedge funds
192
-14
32.20M
+3.26M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 31 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 27 Jul 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Timothy Van Hauwermeiren M.B.A., M.Sc., MSc, EMBA (1972) Chief Executive Officer & Executive Director | $1,130,000 |
| Dr. David Lacey M.D. (1952) Advisor | $56,510 |
Why Johnson & Johnson Stock Still Has Room To Run
Stock Picks From Seeking Alpha's March 2025 New Analysts
Top 4 Immunology Stocks Poised For Growth In 2025
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)
Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation
Argenx: Strong Setup For Outperformance In 2025
Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year
argenx: Innovation Over Losses In Autoimmune Arena
Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
-
What's the price of argenx SE stock today?
One share of argenx SE stock can currently be purchased for approximately $656.89.
-
When is argenx SE's next earnings date?
Unfortunately, argenx SE's (ARGX) next earnings date is currently unknown.
-
Does argenx SE pay dividends?
No, argenx SE does not pay dividends.
-
How much money does argenx SE make?
argenx SE has a market capitalization of 37.40B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 198.56% to 1.23B US dollars. argenx SE made a loss 295.05M US dollars in net income (profit) last year or -$0.7 on an earnings per share basis.
-
What is argenx SE's stock symbol?
argenx SE is traded on the NASDAQ under the ticker symbol "ARGX".
-
What is argenx SE's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of argenx SE?
Shares of argenx SE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are argenx SE's key executives?
argenx SE's management team includes the following people:
- Mr. Timothy Van Hauwermeiren M.B.A., M.Sc., MSc, EMBA Chief Executive Officer & Executive Director(age: 53, pay: $1,130,000)
- Dr. David Lacey M.D. Advisor(age: 73, pay: $56,510)
-
How many employees does argenx SE have?
As Jul 2024, argenx SE employs 1,148 workers.
-
When argenx SE went public?
argenx SE is publicly traded company for more then 8 years since IPO on 18 May 2017.
-
What is argenx SE's official website?
The official website for argenx SE is argenx.com.
-
How can i contact argenx SE?
argenx SE can be reached via phone at +31 10 703 8441.
-
What is argenx SE stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for argenx SE in the last 12 months, the avarage price target is $660. The average price target represents a 0.47% change from the last price of $656.89.
argenx SE company profile:
argenx SE
argenx.comExchange:
NASDAQ
Full time employees:
1,148
Industry:
Biotechnology
Sector:
Healthcare
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Willemstraat 5
Breda, 4811 AH
Breda, 4811 AH
CIK: 0001697862
ISIN: NL0010832176
CUSIP: 04016X101
